Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lisata Therapeutics (LSTA) Invested Capital (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Invested Capital for 12 consecutive years, with $17.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Invested Capital fell 48.04% year-over-year to $17.4 million, compared with a TTM value of $17.4 million through Sep 2025, down 48.04%, and an annual FY2024 reading of $29.3 million, down 38.79% over the prior year.
  • Invested Capital was $17.4 million for Q3 2025 at Lisata Therapeutics, down from $20.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $60.7 million in Q1 2023 and bottomed at $17.4 million in Q3 2025.
  • Average Invested Capital over 3 years is $38.7 million, with a median of $38.0 million recorded in 2024.
  • The sharpest move saw Invested Capital decreased 29.59% in 2024, then crashed 48.04% in 2025.
  • Year by year, Invested Capital stood at $47.9 million in 2023, then tumbled by 38.79% to $29.3 million in 2024, then tumbled by 40.74% to $17.4 million in 2025.
  • Business Quant data shows Invested Capital for LSTA at $17.4 million in Q3 2025, $20.8 million in Q2 2025, and $25.1 million in Q1 2025.